BACKGROUND As diffuse large B-cell lymphoma (DLBCL) is a very heterogeneous group of lymphomas, much effort has gone in trying to identify patients with increased risk for early death or secondary central nervous system (CNS) involvement. To better predict their outcomes, we measured the levels of various cytokines in serum samples of patients with DLBCL and analyzed their clinical outcomes. METHODS We measured the levels of seven serum cytokines at diagnosis in 313 DLBCL patients who were treated with R-CHOP. Their impact on clinical outcomes, including time to secondary CNS involvement and the 3-year overall survival (OS) rate, were analyzed. RESULTS The median age was 56 years (range, 16-86 years), and 177 patients (57%) were men. Secondary CNS involvement was found in 5.4% (16/294) cases, and time to secondary CNS involvement was significantly short in patients with elevated interleukin (IL)-10 (p = 0.012). With the 3-year OS rate of the whole cohort being 73.6%, serum levels of several cytokines, such as CCL3 > 4.0 pg/mL (54.3% vs. 76.1%, p = 0.001), CCL5 > 450 pg/mL (57.0% vs. 78.1%, p < 0.001), any expression of IL-6 (59.3% vs. 76.6%, p = 0.001), and any expression of IL-10 (68.2% vs. 84.5%, p = 0.001), showed prognostic impact. Higher expressions of these cytokines were associated with worse manifestations of clinical prognostic factors. CONCLUSIONS Our study revealed that some cytokines impact OS and secondary CNS involvement. Future studies are required to elucidate how these findings can be incorporated to the conventional prognostic factors for more tailored approaches.

中文翻译：

---

治疗前血清IL-10预测弥漫性大B细胞淋巴瘤患者继发性中枢神经系统受累的风险

背景 由于弥漫性大 B 细胞淋巴瘤 (DLBCL) 是一组异质性很强的淋巴瘤，因此在识别早期死亡或继发性中枢神经系统 (CNS) 受累风险增加的患者方面付出了很多努力。为了更好地预测他们的结果，我们测量了 DLBCL 患者血清样本中各种细胞因子的水平并分析了他们的临床结果。方法 我们测量了 313 名接受 R-CHOP 治疗的 DLBCL 患者在诊断时的七种血清细胞因子水平。分析了它们对临床结果的影响，包括继发性 CNS 受累时间和 3 年总生存率 (OS)。结果 中位年龄为 56 岁（范围，16-86 岁），177 名患者（57%）为男性。在 5.4% (16/294) 的病例中发现继发性中枢神经系统受累，白细胞介素 (IL)-10 升高的患者继发中枢神经系统受累的时间显着缩短 (p = 0.012)。整个队列的 3 年 OS 率为 73.6%，几种细胞因子的血清水平，如 CCL3 > 4.0 pg/mL（54.3% vs. 76.1%，p = 0.001），CCL5 > 450 pg/mL（57.0 % 与 78.1%，p < 0.001），IL-6 的任何表达（59.3% 与 76.6%，p = 0.001），以及 IL-10 的任何表达（68.2% 与 84.5%，p = 0.001），显示预后影响。这些细胞因子的较高表达与临床预后因素的较差表现相关。结论 我们的研究表明，一些细胞因子会影响 OS 和继发性 CNS 受累。未来的研究需要阐明如何将这些发现与传统的预后因素相结合，以获得更量身定制的方法。